SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
LGVN

Longeveron Inc. (NASDAQ:LGVN)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.66-$0.16 (-8.79%)
 
Market cap
$5.37M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 12, 2021
Market Cap$5.37M-73.4%
Revenue (ttm)$1.17M-18.9%
Net Income-$22.39M-4.9%
EPS-$8.11+39.0%
Shares Out3.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume27,258
Open$1.83
Previous Close$1.82
Day's Range$1.64 - $1.83
52-Week Range$1.31 - $12.30
Betan/a
AnalystsBuy
Price Target$10.00(+502.41%)
Earnings DateMar 16, 2027
-8.79% (1D)
No price history available.

About LGVN

Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.

Address
Life Science & Technology Park, Miami, FL, 33136, US
Market Cap
5 million
Employees
38
Industrial Classification
Biotechnology
Financial Health Score
Weak
From LGVN’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-8.79%
5 Days
-31.12%
1 Month
+4.40%
6 Months
-79.76%
1 Year
-73.44%

$LGVN stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in LGVN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by LGVN's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

LGVN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

LGVN Revenue by Segment

$10.12MTotal
R&D costs$3.96M39.12%
G&A costs$3.31M32.71%
Personnel costs$2.85M28.17%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New LGVN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to LGVN from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in LGVN

VXFVanguard Extended Market ETF$61.22K
VTIVanguard Morningstar Total Stock Market ETF$47.55K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from LGVN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
100% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.